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Abstract Synthetic peptides immobilized on cellulose mem- 
branes proved to be a powerful tool for the identification of sites 
in the cytokine IL-6 involved in receptor binding. Similarly, a 
region in the extracellular part of the IL-6 receptor which is 
important for interaction with its ligand was identified. 
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1. Introduction 
Protein-protein interactions have been studied by a multi- 
tude of methods. Crosslinking experiments, competition studies 
with monoclonal antibodies, site-directed mutagenesis, X-ray 
crystallography, fluorescence-, mass- and NMR-spectroscopy 
have been powerful approaches. 
Since we have been interested in structure-function studies 
on the cytokine interleukin-6 and its receptor for several years 
[l-6], we have now applied the use of synthetic peptides co- 
valently linked to cellulose membranes [7,8] in order to identify 
contact sites between IL-6 and its receptor. 
IL-6 exerts pleiotropic activities in hematopoiesis, in the im- 
mune response and in the acute phase reaction of the liver 
[9-l 11. These functions are mediated via a two-component cell 
surface receptor complex consisting of a ligand binding a sub- 
unit (gp80, IL-6R) and a signal transducing protein (gpl30) 
1121. 
IL-6 is known to belong to a family of hematopoietic cytok- 
ines adopting an a-helix bundle structure. The four major a- 
helices of the molecule are arranged in an up-up-down-down 
topology [13]. The IL-6 receptor, on the other hand, is a mem- 
ber of the immunoglobulin superfamily, i.e. its extracellular 
part consists of one distal IgG-like domain and two proximal 
fibronectin type III modules constituting an IL-6 binding 
pocket and thus referred to as a cytokine binding domain [14]. 
The receptor interaction site of IL-6 appears to be made up 
of crucial residues in helix A, in the C-terminal part of the 
AB-loop and at the end of helix D [l-3,5,15-18]. The corre- 
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sponding surface on the IL-6 receptor is formed by residues in 
the B’C’-loop and adjacent C-strand as well as in the DE’- and 
F’G’-loops of the second cytokine binding domain ([19]; M. 
Kalai et al., submitted for publication). 
In the work presented we were able to identify two regions 
in the IL-6 molecule and one region in the IL-6 receptor which 
form contact sites in the ligand-receptor complex using immo- 
bilized synthetic peptide fragments of the two proteins. 
2. Materials and methods 
2.1. Iodination of human IL-6 and sIL-6R 
Human recombinant IL-6 was expressed in E. coli and purified from 
inclusion bodies as described in [20]. A specific activity of lo’-lo9 units 
per mg of protein was determined in the B9 cell proliferation assay [21]. 
Soluble IL-6R was purified to homogeneity from conditioned media of 
baculovirus-infected Sf9 cells by affinity chromatography [22]. Iodina- 
tion of both probes was performed according to [23]. Specific activities 
of 0.5 MBq/pg and 0.8 MBq/pg were obtained for IL-6 and sIL-6R, 
respectively. 
2.2. Synthesis of peplides immobilized IO cellulose membranes 
The cellulose-bound peptides were prepared automatically according 
to standard spot synthesis protocols [7] using a spot synthesizer (Abi- 
med GmbH, Langenfeld, Germany) as described in detail previously 
181. 
2.3. Probing of membrane-bound peptides for [‘2sI]sIL-6R- or 
[“‘I]IL-6 binding 
Membranes were rinsed with methanol and washed three times with 
TBS (137 mM NaCl, 2.7 mM KCl, 50 mM Tris-HCl, pH 8.0). To 
prevent unspecific binding the membranes were incubated overnight in 
blocking buffer (Cambridge Research Biochemicals, Gadbrook Park, 
UK) containing 0.15 M sucrose, 0.05% Tween 20 and 0.01% NaN,. 
Followina another washing sten in T-TBS (TBS containing 0.05% 
Tween 205, membranes wereassayed for binding activity by in&bation 
with the interacting ‘ZSI-labelled protein in blocking buffer for 3 h at 
room temperature. After three washes in T-TBS, bound radioactivity 
was visualized by exposure to an X-ray film for 24-72 h. 
3. Results 
In order to analyze the sites of interaction between IL-6 and 
its a receptor subunit (ILdR), dodecapeptides spanning the 
whole IL-6 sequence and overlapping by nine amino acids were 
synthesized on a cellulose membrane support. A soluble form 
of the IL-6R, which we have expressed in baculovirus-infected 
insect cells, was radiolabelled with lz51 and used to probe the 
membrane for binding activity. Bound radioactivity was visual- 
ized by autoradiography (Fig. 1A). Binding of [‘251]sIL-6R to 
IL-6 peptides essentially focuses on two distinct regions com- 
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Fig. 1. Spotscan of membrane-bound IL-6-derived dodecapeptides with [‘251]sIL-6R. (A) 59 dodecapeptides spanning the entire IL-6 amino acid 
sequence were synthesized as described in section 2. Peptides on adjacent spots differ by a shift of three amino acids from each other, i.e. they overlap 
by nine amino acids. Numbers denote the first and last spot in each row. The membrane was incubated with 20 ng of [‘2*I]sIL-6R (specific activity 
0.8 MBq/pg) per ml of blocking buffer. After extensive washing, bound radioactivity was visualized by autoradiography. (B) Schematic representation 
of the amino acid sequence (top) and the predicted secondary structure elements (bottom) of IL-6 [13] corresponding to peptides #29 to #34, and 
#S6 to #59. The radioactivity on each spot (background subtracted) is indicated. 
prised in the peptides #30 to #33, and #56 to #59, respectively. 
The location of these overlapping peptides within the sequence 
of IL-6 and predicted secondary structure elements [13] are 
indicated in Fig. lB, lower part; the first of the two regions of 
interest (I&,,,) is localized at the C-terminal part of helix B 
and the adjacent BC-loop, whereas the second one (L,65-M,84) 
corresponds to the C-terminus of the molecule. 
To further characterize these two regions with respect to the 
residues essential for binding, mutation experiments were per- 
formed with dodecapeptides G,,-L,,, and F,73-M,84. Each res- 
idue was separately exchanged for each of the 20 amino acids. 
The results are shown in Fig. 2. In the GgO-L,,, peptide (Fig. 
2A), all three glutamic acids are obviously essential for binding 
of [‘2sI]sIL-6R, since any substitution except for aspartic acid 
abolishes binding. Introduction of additional negative charges 
(E or D) in many positions increases bound radioactivity above 
the level of the native peptide, most impressively at positions 
L,,, Y,,, LY8 and YiO,. On the other hand, V,, does not tolerate 
exchanges for charged amino acids; hydrophobic or small polar 
side chains are preferred at this position. In the second peptide 
mutated (F,,,-M,,,) (Fig. 2B), R,,g and R,,, are least tolerant 
towards mutations, which reflects their crucial role in [‘251]sIL- 
6R binding. All substitutions except for K decrease or abolish 
binding of labelled IL-6 receptor. Thus far, we and others were 
unsuccessful in solving the 3D structure of IL-6 either by NMR 
spectroscopy or X-ray crystallography. A model of IL-6 has 
been built with the X-ray structure of G-CSF [24] as a template 
[5]. The regions of IL-6 (black) which we found to be involved 
in receptor binding are shown in the model of the IL-6/IL-6R 
complex (Fig. 4, left part). 
An analogous approach was used to elucidate the ligand 
binding epitopes on the IL-6R molecule: membrane-bound 
tridecapeptides derived from the two ligand binding domains 
of the IL-6R were scanned with [‘*‘I]IL-6 (Fig. 3A). Bound 
radioactivity was mainly detected in one cluster of spots (#80 
to #87). Fig. 3B shows the localization of this epitope within 
the primary and predicted secondary structure of the IL-6R 
[14]. The region of interest comprises residues W,,,K,,, and 
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Fig. 2. Spotscan of point-mutated IL-6 peptides with [‘Z51]sIL-6R. In peptides G,,-L,,, (A) and F,,,-M,,, (B) defined in Fig. 1 each residue was 
separately exchanged by each of the 20 proteinogenic amino acids. The positions mutated are indicated at the left, the amino acids inserted instead 
are shown on top of the autoradiography. The membranes were probed for [‘2SI]sIL-6R binding, as in the previous experiment. 
extends over B-strands C’ and D’ and the B’C’- and C’D’-loops. 
This stretch on the IL-6R molecule is marked in black in 
Fig. 4, right part. 
4. Discussion 
In this study, an approach using immobilized synthetic pep- 
tides was used to investigate the protein-protein interaction in 
a cytokine-receptor system. Applying this technique to human 
IL-6 and its receptor, we were able to confirm results obtained 
by other methods: the extraordinary importance of the C-termi- 
nus of IL-6 for IL-6R binding, especially of R,,, and R,,, 
[2,3,16-181 is clearly demonstrated by our results. The second 
IL-6 region that appears to be involved in the interaction with 
IL-6R (end of B-helix, BC-loop) has also been described before 
[25]. In this region, our point mutational scan suggests a major 
role of three glutamic acid residues in IL-6R binding. Parts of 
helix A and of the AB-loop have been identified to be involved 
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identified in this study, in order to evaluate their interference 
with ligand binding and signal transduction. They found pep- 
tide Y,,,-TZ4, to inhibit biological effects of IL-6, such as acute 
phase protein synthesis in HepG2 cells and B9 cell prolifera- 
tion. They did, however, not detect any impairment of IL-6 
binding to U266 cells, which should have been expected from 
the results presented here. This discrepancy might be due to the 
higher sensitivity of our approach concerning the detection of 
protein-protein interaction. A soluble peptide starting at YZ3,, 
displays the putative IL-6 binding residues at the N-terminus. 
Moreover, the N-terminal Y,,,, that obviously is involved in the 
interaction with IL-6, is associated with the positive charge of 
its underivatized amino group. Both factors might lead to re- 
duced affinity for the ligand due to conformational problems. 
On the other hand, in the microenvironment at the cellulose 
membrane surface, synthetic peptides are present at extremely 
high concentrations resulting in a detectable ligand avidity in 
spite of a relatively low physical affinity. Other loops (DE’ and 
F’G’) in the IL-6R molecule involved in the interaction with 
IL-6 [19] could not be identified by our approach. 
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Fig. 3. Spotscan of sIL-6R-derived tridecapeptides with [“‘I]sIL-6. 
(A) Membrane-bound tridecapeptides overlapping by ten amino acids 
were probed with [“‘I]IL-6 (30 @ml) specific activity 0.5 MBq/,ug), fol- 
lowed by extensive washing and autoradiography. (B) Schematic map- 
ping of peptides #80 to #87 to the primary (top) and predicted second- 
ary structure (bottom) of the IL-6R [14]. 
in ILdR binding [5,26]. These regions within the IL-6 molecule 
could not be detected by our spot scan technique, probably 
because they are parts of discontinuous epitopes. Although the 
position of the IL-6R in our model (Fig. 4) is validated by our 
results (Fig. 1, end of helix D) and by various experimental data 
[3,5,15,26], our results on the BC-loop interaction of IL-6 with 
the ILdR may suggest that the model shown in Fig. 4 is incom- 
plete. Consequently, a second IL-6R molecule may interact 
with this region. 
In the IL-6R molecule, we found the stretch of residues 
W,,,K,,, implicated in IL-6 binding. With respect to the three- 
dimensional topology illustrated in Fig. 4, right part, involve- 
ment of such an extended region in ligand binding seems rather 
unlikely, since the end of strand C’, the CD’-loop and strand 
D’ are not exposed to the ligand binding surface as presumed 
on the basis of a molecular modelling approach using the crys- 
tal structure of the human growth hormone/receptor complex 
[27]. Point mutations in the IL-6R molecule revealed the impor- 
tance of Y,,, and R,,, for ligand interaction ([19]; M. Kalai et 
al., submitted for publication). Among the peptides with IL-6 
binding activity, #80 to #85 at least partly comprise these 
crucial residues. 
The positive signal from the peptides #86 and #87 is most 
probably due to the presence of two motives (R237YRAE241 and 
R,,,SKTF,,,) mimicking the R,,,LRFE,,, sequence in the IL-6 
binding pocket. Obviously, the presence of two positively 
charged amino acids with one uncharged residue in between is 
sufficient for IL-6 binding. Grube et al. [28] used soluble syn- 
thetic peptides, which are also comprised by the IL-6R region 
Our results, of course, do not rule out a potential role of 
residues further downstream in the ILdR sequence, e.g. in 
strand C’ or the C’D’-loop, in the interaction with gp130. Al- 
though we were able to find peptides in IL-6 as well as in the 
IL-6 receptor important for ligand-receptor interaction, the 
results obtained by this technique have to be interpreted with 
caution. Discontinuous epitopes are hard to detect by an ap- 
proach using linear (and relatively short) peptides instead of the 
intact protein. Moreover, regions of a molecule that are not 
surface-exposed in the native structure will be displayed on the 
spot membrane and may therefore evoke positive signals al- 
though they are not implicated in protein-protein interaction. 
Fig. 4. A ribbon representation of a model of the IL-6/IL-6R complex 
which was built using the hGH/hGHR complex as a template ([5,27]; 
Griitzinger, J. et al., submitted for publication). Binding sites on the 
IL-6 (left) and IL-6R (right) molecules identified in this study are shown 
in black. The 4 helices of IL-6 are denoted A, B, C, D. 
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Nonetheless, the peptide scan approach is a fast and rela- 
tively simple screening tool that can provide valuable informa- 
tion on ligand-receptor interaction sites. 
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